Trial Profile
Treatment of Poor Risk Myelodysplasia With the Combination of Amifostine, Topotecan and ARA-C: A Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Jul 2016
Price :
$35
*
At a glance
- Drugs Amifostine (Primary) ; Cytarabine (Primary) ; Topotecan (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- Sponsors ALZA Corporation
- 28 Jul 2016 New trial record